Chapter 271 - 207: Rejecting the 3 Major Pharmaceutical Groups for an Independent, Self-Sufficient R&D Path

Chapter 271: Chapter 207: Rejecting the 3 Major Pharmaceutical Groups for an Independent, Self-Sufficient R&D Path

But could a project on the scale of curing primary liver cancer caused by Hepatitis B truly be accomplished by Wu Ting founding a company all on his own?

Xie Bin, of course, didn’t believe Wu Ting had that kind of courage and capability. He did, however, admire Jin Yihong and her daughter for proposing such a partnership model.

In the conference room, Xie Bin, Deng Feifei, and the other two representatives waited for Wu Ting’s final decision.

Wu Ting looked at Deng Feifei’s proposal and began to weigh his options. ’Based on my current results, my phase-four theory is more or less complete. The only thing missing is the phase-three research and development for the new drug, Fengmu Tiada.’

’To start, the results from phases one, two, and four, along with Wu’s Umbilical Knife and the core methodology for the perfect triple-combination adjuvant technology, are enough to support a startup company.’

’With the first-phase investment of 20 million from the Jin Pharmaceutical Group, a 10 million grant from a key project of the National Natural Science Foundation, and continuous funding from the HHMI Research Institute, it would be enough to launch the initial research.’

’Then, once the company becomes profitable, it would be a natural next step to raise more funds and proceed with the research and development of the new Fengmu Tiada drug.’

’As for the R&D technology of top conglomerates like Pfizer and Johnson & Johnson, I’m not worried in the slightest. I just need to acquire the corresponding system entries.’

’And as for those entries, there are plenty of experts at both the Deng Fujiu Research Institute and the HHMI Research Institute that I can grind them from.’

What Wu Ting valued most about the new joint venture with the Jin Pharmaceutical Group was a key point in the proposal: he would contribute his technology and patents as capital, giving him a fifty-one percent absolute controlling stake.

By using this joint venture as the parent company to manage all other commercial activities through subsidiaries, his independence and autonomy would be completely guaranteed.

Of course, the most critical factor was what Deng Feifei had said: "Making technological self-reliance and self-improvement the strategic pillar of national development, and accelerating our rise as a technological powerhouse!"

Other scientists might worry about their own limitations and research capabilities, but Wu Ting was different. He possessed the ultimate core technology!

Amid the hopeful anticipation of the four pharmaceutical group representatives, Wu Ting made his decision.

"President Deng, I accept the invitation from the Jin Pharmaceutical Group. We can start by reaching a preliminary agreement of intent. The specific details of the partnership can be fleshed out later."

"Furthermore, in addition to your company, I will also invite the Jinggang University Medical College and my old institution, Fan City First Hospital, to collaborate on this great project!"

Wu Ting expressed his stance, his voice filled with fighting spirit and national pride.

The representatives from the three major pharmaceutical corporations clearly hadn’t expected Wu Ting to be a man so driven by his convictions, but they admired his confidence and talent nonetheless.

Xie Bin, for his part, shook Wu Ting’s hand, his expression a mixture of regret and anticipation.

"Dr. Wu, I will report your decision to the board of directors at headquarters."

"Dr. Wu, it’s a shame we couldn’t reach an agreement. I suppose the next time we meet, we’ll be business rivals."

...

...

After Wu Ting and the Jin Pharmaceutical Group signed the preliminary framework agreement, the news immediately caused a massive uproar online.

"Dr. Wu Ting, a young immunologist from the Jinggang University Medical School Graduate School, published a feature article in *Cell* proposing a groundbreaking negative immune regulatory mechanism. The news attracted three major international pharmaceutical giants seeking a partnership, but Dr. Wu refused them all, choosing instead to establish a domestic pharmaceutical company in Jin Country..."

"Dr. Wu Ting and Jin Province’s own Jin Pharmaceutical Group have reached a partnership agreement to establish an independent, globally-leading pharmaceutical company! Is it courage or recklessness?"

"Deng Feifei, the sole heiress of the Jin Pharmaceutical Group, has joined Wu Ting’s new company as its technology manager to co-found a startup in the field of primary liver cancer caused by Hepatitis B!"

...

...

All kinds of news and opinions flew wildly across the internet. There was encouragement, support, and doubt. Some even felt that Wu Ting had thrown away a heaven-sent, life-changing fortune.

On the very day Wu Ting and the Jin Pharmaceutical Group signed their partnership agreement, the official website of the Jinggang University Medical College also published a shocking announcement:

"The Haijin Port Future Innovation Master Fund will provide an initial investment of 10 million for Dr. Wu Ting’s team!"

Jinggang University alumni had founded or managed over a hundred publicly listed companies. In this year’s Hurun Alumni Rich List, Jinggang University ranked first with 38 alumni making the list!

Through the joint efforts of Dean Song and the Jin Pharmaceutical Group, it was a natural outcome for Wu Ting to secure this 10 million in investment support!

Once Deng Feifei helped Wu Ting officially register and establish the new Wu’s Pharmaceutical Company, the relevant funds would be transferred on schedule!

The first phase of funding from the Jin Pharmaceutical Group was also confirmed to be 20 million in total!

It was hard to believe. Everything was still in the planning stages, without even a shadow of a laboratory in sight, yet Wu Ting had already amassed so much financial backing through the influence of the Jin Pharmaceutical Group, Dean Song, and others.

On top of that, there was still the 10 million from the National Natural Science Foundation’s key project, and at least one million US dollars a year in support from the HHMI.

Wu Ting himself felt a sense of unreality. ’The road ahead is long and winding!’

’Next, I need to go back to City First Hospital, discuss things with Dean Tang and Director Cai, and get the primary liver cancer lab established there!’

Later on, this lab would also bring in relevant departments from the Jinggang University Affiliated First Hospital for collaboration.

It was like following the same path he’d taken with the Research Center for Laparoscopic Diagnosis and Treatment Technology. The difference was that last time, Ma Mengchao had been the one calling all the shots. This time, however, Wu Ting could finally run the show himself!

All the funding, the entire network of connections, and all the core technology—it all revolved around Wu Ting!

...

...

To better coordinate the upcoming establishment of Wu’s Pharmaceutical Company and its subsequent operations, Deng Feifei began working alongside Wu Ting every day.

Deng Feifei personally drove Wu Ting back to Fan City First Hospital.

After returning to City First Hospital, Wu Ting wasn’t in a hurry to see the hospital leadership. He first went to the wards. As chief resident, he still needed to be on the front lines and regularly check in on the patients under his care.